MedTrace Logo

Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis

NCT05340985 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2022-04-22

No results posted yet for this study

Summary

Investigating the effects of hydroxyvitamin D3 on clinical, radiologic and immunomodulatory markers in MS patients: A randomized, clinical trial- a pilot study

Conditions

  • Multiple Sclerosis, Relapsing-Remitting
  • Adult ALL
  • Vitamin D3 Deficiency

Interventions

DIETARY_SUPPLEMENT

25(OH)D3

calcifediol

DIETARY_SUPPLEMENT

vitamin D3

Cholecalciferol

Sponsors & Collaborators

  • Boston University

    collaborator OTHER

  • Tehran University of Medical Sciences

    lead OTHER

Principal Investigators

  • Mohamadali Sahraian, MD · Multiple Sclerosis Research Center, Tehran University of Medical Sciences

  • Zhila Maghbooli, PhD · Multiple Sclerosis Research Center, Tehran University of Medical Sciences

  • Michael F Holick, PhD,MD · Boston University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-31
Primary Completion
2023-06-30
Completion
2023-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05340985 on ClinicalTrials.gov